Login to Your Account

Allergan Snags MAP for $958M, Targets Migraine Franchise

By Marie Powers
Staff Writer

Thursday, January 24, 2013
Anticipating a thumbs-up from the FDA on acute migraine drug Levadex and building from an existing co-promotion arrangement, Allergan Inc. is purchasing MAP Pharmaceuticals Inc. in a cash deal, acquiring the company's shares at $25 each.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription